RTP Mobile Logo
Year in Review – Non-Hodgkin’s Lymphomas: 2009-2010
Released December 2010

Year in Review is a unique CME activity that attempts to distill the overwhelming number of data sets and journal articles in non-Hodgkin’s lymphoma published in 2009 and 2010 into a convenient summary of the most clinically relevant papers and presentations. Featuring commentary from Drs Richard I Fisher, Francine Foss and Julie M Vose. (Text and Slide Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Given the prevalent nature of the disease, extensive resources are allocated to hematologic cancer research and education. The current utility of cytotoxic chemotherapies, autologous and/or allogeneic hematopoietic stem cell transplant and biologic or molecular-targeted therapies has been the focus of treatment algorithms designed to assist clinicians in the care of patients with non-Hodgkin’s lymphomas (NHL). The variety of recognized practical management scenarios for NHL may cause clinician confusion and controversy. Educational opportunities relevant to the clinical management of NHL are essential to general oncologists’ delivery of comprehensive cancer care. To bridge the gap between research and patient care, this CME activity uses the input of cancer experts and community physicians to frame a relevant discussion of recent research advances in hematologic cancer that can be applied to routine clinical practice. This information will help medical oncologists, hematologists and hematology-oncology fellows formulate up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Appraise recent data on therapeutic advances and changing practice standards in NHL, including chronic lymphocytic leukemia (CLL), and apply this information to clinical practice.
    • Use prognostic and predictive clinical and molecular markers to aid in treatment decision-making for NHL.
    • Individualize the use of maintenance and/or consolidation therapy in the management of newly diagnosed and relapsed follicular lymphoma.
    • Recall the emerging data for novel agents and combinations in the treatment of mantle-cell lymphoma.
    • Develop an algorithm for the risk-stratified induction treatment of diffuse large B-cell lymphoma.
    • Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed or relapsed/refractory CLL.
    • Communicate the benefits and risks of evidence-based systemic treatments to patients with advanced cutaneous or peripheral T-cell lymphoma.
    • Identify patients with NHL who may experience quantitative and qualitative benefit from salvage therapy regimens with stem cell transplantation.


    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY


    CME credit is no longer available for this issue

    This CME activity contains print and web PowerPoint components. The participant should read the text portion. The text portion of this activity contains edited comments and abbreviated slide set presentations, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    COMMERCIAL SUPPORT


    This program is supported by educational grants from Celgene Corporation and Genentech BioOncology/Biogen Idec.

    PHARMACEUTICAL AGENTS DISCUSSED IN THIS PROGRAM


    This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY
    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FisherConsulting Agreements: Millennium Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc. Dr FossAdvisory Committee: Allos Therapeutics; Speakers Bureau: Allos Therapeutics, Celgene Corporation, Eisai Inc. Dr VosePaid Research: Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Genzyme Corporation, GlaxoSmithKline, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics Inc, US Biotest Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2010
    Expiration date: December 2011

Acknowledge and close

View slides: